Skin cancer is diagnosed through a combination of visual examination, biopsy, and lab analysis. The process typically starts with a doctor inspecting a suspicious spot on your skin, either during a routine check or after you notice something unusual. If the spot looks concerning, a small tissue sample is removed and sent to a pathologist, whose microscopic analysis provides the definitive answer.
The Visual Exam: What Doctors Look For
The first step is a careful look at the suspicious area, often with the naked eye and then with a handheld magnifying device called a dermatoscope. This tool uses polarized light to reveal structures beneath the skin’s surface that aren’t visible otherwise, and it makes a meaningful difference. A Cochrane review found that combining dermoscopy with visual inspection improved diagnostic accuracy by about 16 percentage points for correctly identifying melanomas and 20 percentage points for correctly ruling out non-cancerous spots, compared to visual inspection alone.
For melanoma specifically, doctors use a framework called the ABCDE rule to evaluate moles and pigmented spots:
- Asymmetry: One half of the spot doesn’t match the other.
- Border: The edges are ragged, notched, or blurred rather than smooth.
- Color: The color is uneven, with mixtures of black, brown, tan, white, gray, red, pink, or blue.
- Diameter: The spot is larger than about 6 millimeters (roughly the size of a pencil eraser), though melanomas can be smaller.
- Evolving: The spot has changed in size, shape, or color over recent weeks or months.
Not every spot that meets one of these criteria is cancer, and not every skin cancer follows this pattern neatly. Basal cell carcinomas, for instance, often appear as pearly bumps or flat, flesh-colored lesions rather than dark moles. Squamous cell carcinomas can look like firm red nodules or rough, scaly patches. The visual exam narrows down what’s suspicious, but it can’t confirm a diagnosis on its own.
The Biopsy: Getting a Definitive Answer
If a spot looks suspicious, the next step is a biopsy, where a small sample of tissue is removed and sent to a lab. This is the only way to confirm whether skin cancer is present. There are three main types, and the one your doctor chooses depends on the type of cancer they suspect and how deep they think it goes.
A shave biopsy removes a thin layer from the topmost part of the skin using a small blade. It’s commonly used when basal cell or squamous cell carcinoma is suspected and the lesion appears superficial. A punch biopsy uses a small circular tool to remove a deeper, round plug of tissue. This is also used for suspected basal or squamous cell cancers, particularly when a deeper sample is needed. An excisional biopsy removes the entire suspicious area with a scalpel. This is the preferred approach when melanoma is suspected, because it captures the full depth and width of the lesion for accurate analysis.
What the Biopsy Feels Like
The area is numbed with a local anesthetic, typically injected with a small needle. The injection itself is the most uncomfortable part for most people. Some doctors apply a numbing cream 30 to 60 minutes beforehand, though this works best for shallow shave biopsies. For deeper punch or excisional biopsies, an injection is usually necessary to fully numb the area.
The biopsy itself takes only a few minutes. Shave and punch biopsies are quick office procedures. Excisional biopsies take a bit longer since the area may need stitches. Afterward, you’ll go home with simple wound care instructions: gently wash the area and apply petroleum jelly with a bandage. If stitches were placed, they’re typically removed in one to two weeks.
Results come back in a few days in most cases, though more complex tests can take longer. Waiting for results is often the hardest part of the process.
What the Pathology Report Reveals
A pathologist examines the tissue sample under a microscope to determine whether cancer cells are present, what type of skin cancer it is, and how aggressive it appears. If the diagnosis is melanoma, the report includes several key measurements that guide treatment decisions.
The most important is Breslow depth, which measures the thickness of the melanoma at its thickest point in millimeters. Thinner melanomas have a significantly better prognosis. A melanoma less than 0.8 mm thick that isn’t ulcerated is considered very early stage, while one thicker than 4 mm is more advanced. The report also notes whether the skin over the tumor is ulcerated (broken down), which tends to indicate a more aggressive cancer even at the same thickness.
Another factor is the mitotic rate, which tells how quickly the cancer cells are dividing. A higher rate means faster-growing cells and a greater chance the cancer could spread. This measurement is considered the second most important prognostic factor after Breslow depth and is especially useful for staging very thin melanomas under 1 mm thick.
For non-melanoma skin cancers like basal cell and squamous cell carcinoma, the pathology report focuses on the cancer type, how deep it extends, and whether the edges of the removed tissue are clear of cancer cells.
Staging: How Far Has It Spread?
Once skin cancer is confirmed, doctors determine its stage using the TNM system, which stands for Tumor, Node, and Metastasis. This framework captures three things: how thick and ulcerated the primary tumor is, whether cancer cells have reached nearby lymph nodes, and whether the cancer has spread to distant organs like the lungs or liver.
For melanoma, the tumor categories range from Tis (melanoma in situ, confined to the very top layer of skin) through T4 (thicker than 4 mm). Each category from T1 through T4 is further split into “a” (no ulceration) and “b” (ulcerated), because ulceration independently worsens the outlook. The node categories range from N0 (no cancer in lymph nodes) to N3 (cancer in four or more lymph nodes or lymph nodes that have clumped together). Metastasis is either M0 (no distant spread) or M1 (cancer found in other parts of the body).
For melanomas at least 0.8 mm thick with no obvious lymph node involvement, doctors often recommend a sentinel lymph node biopsy. This procedure identifies and removes the first lymph node that drains from the tumor site to check whether cancer cells have traveled beyond the skin. The result plays a major role in determining whether additional treatment is needed.
Newer Non-Invasive Tools
Reflectance confocal microscopy is an FDA-approved imaging tool that lets doctors examine skin at near-cellular resolution without cutting into it. It works somewhat like an optical biopsy, revealing structural details of common skin cancers including melanoma, basal cell carcinoma, and squamous cell carcinoma. Its primary value is helping doctors distinguish cancerous spots from benign ones like ordinary moles, age spots, or seborrheic keratoses, potentially reducing unnecessary biopsies. It’s available at specialized dermatology centers rather than every doctor’s office, and it supplements rather than replaces traditional biopsy when cancer is strongly suspected.